Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects
NCT00084058Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of lopinavir + ritonavir and saquinavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Life-threatening adverse events attributable to study drugs and Dose-limiting toxicity. Status: completed.
02
Drugs
lopinavir + ritonavirsaquinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00084058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084058.